Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
The Chan Zuckerberg Biohub is both an institute and an academic network devoted to accelerating research via cutting edge technologies and open science. Its focus on single-cell analysis and infectious disease has placed it front and center in the pandemic.
Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
The biopharmaceutical industry’s positive regulatory momentum carried on through 2019, despite an early-year government shutdown, a data manipulation scandal around a high-profile approval, and many months without permanent leadership at the FDA.
The FDA approved record numbers of new molecular entities, orphan drugs, small-molecule generics and biosimilars in 2018. Could industry’s regulatory success of the past two years become the new normal?
Ambitious efforts to catalog viruses across the globe may facilitate our understanding of viral communities and ecology, boost infectious disease diagnostics and surveillance, and spur new therapeutics. Charles Schmidt investigates.
A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.
Mitochondrial replacement therapy is being touted as a means of combating maternally inherited disease. But concerns are growing about mitochondrial reversion compromising cures. Steve Connor investigates.
Despite last year's sharp decline in approvals, registrations of two RNA drugs offer a window into the current state and possible future of drug development. Looking forward, the sector seeks greater clarity on the new presidential administration's priorities and the impact of new healthcare legislation. Chris Morrison reports.
Spanish researchers are testing GM low-gliadin wheat for gluten-allergy sufferers. But stifling EU bureaucracy and adoption challenges may mean an uphill struggle to market. Lucas Laursen investigates.
The recent publication of a simple procedure for creating a CRISPR-Cas9-mediated gene drive has some researchers sounding the alarm. What are the risks to populations in the wild and what precautions are necessary? Laura DeFrancesco investigates.
Personal health data are beginning to be shared in the digital world—on mobile devices and the internet. Is the loss of privacy a price worth paying for the presumed benefits? Laura DeFrancesco investigates.
Using conventional drug discovery and novel synthetic biology approaches, some investigators and companies are mining our resident microbes and their metabolites for targets in small-molecule drug programs. Ken Garber reports.